Vaccine strategies against cystic fibrosis pathogens

References

• Riordan JR, Rommens JM, Kerem B, Alon N, Rozmahel R, Grzelczak Z, Zielenski J, Lok S, Plavsic N, Chou JL, et al. Identification of the cystic fibrosis gene: cloning and characterization of complementary DNA. Science 1989; 245:1066-73; PMID:2475911; http://dx.doi.org/10.1126/science.2475911.
   PubMed Web of Science ®Google Scholar
• Ratjen FA. Cystic fibrosis: pathogenesis and future treatment strategies. Resp Care 2009; 54:595-602; PMID:19393104; http://dx.doi.org/10.4187/aarc0427.
   PubMed Web of Science ®Google Scholar
• Rowe SM, Miller S, Sorscher EJ. Cystic fibrosis. N Engl J Med 2005; 352:1992-2001; PMID:15888700; http://dx.doi.org/10.1056/NEJMra043184.
   PubMed Web of Science ®Google Scholar
• May JR, Herrick NC, Thompson D. Bacterial Infection in cystic fibrosis. Arch Dis Child 1972; 47:908-13; PMID: 4630478; http://dx.doi.org/10.1136/adc.47.256.908.
   PubMed Web of Science ®Google Scholar
• Marks MI. Clinical significance of Staphylococcus aureus in cystic fibrosis. Infection 1990; 18:53-6; PMID: 2107147; http://dx.doi.org/10.1007/BF01644186.
   PubMed Web of Science ®Google Scholar
• LiPuma JJ. The changing microbial epidemiology in cystic fibrosis. Clin Microbiol Rev 2010; 23:299-323; PMID:20375354; http://dx.doi.org/10.1128/CMR.00068-09.
   PubMed Web of Science ®Google Scholar
• Roux AL, Catherinot E, Ripoll F, Soismier N, Macheras E, Ravilly S, Bellis G, Vibet MA, Le Roux E, Lemonnier L, et al. Multicenter study of prevalence of nontuberculous mycobacteria in patients withcystic fibrosis in France. J Clin Microbiol 2009; 47:4124-8; PMID:19846643; http://dx.doi.org/10.1128/JCM.01257-09.
   PubMed Web of Science ®Google Scholar
• Olivier KN, Weber DJ, Lee JH, Handker A, Tudor G, Molina PL, Tomashefski J, Knowles MR; Nontuberculous Mycobacteria in Cystic Fibrosis Study Group. Nontuberculous mycobacteria. Am J Respir Crit Care Med 2003; 167:835-40; PMID:12433669; http://dx.doi.org/10.1164/rccm.200207-679OC.
   PubMed Web of Science ®Google Scholar
• Gibson RL, Burns JL, Ramsey BW. Pathophysiology and management of pulmonary infections in cystic fibrosis. Am J Respir Crit Care Med 2003; 168:918-51; PMID:14555458; http://dx.doi.org/10.1164/rccm.200304-505SO.
   PubMed Web of Science ®Google Scholar
• Drenkard E. Antimicrobial resistance of Pseudomonas aeruginosa biofilms. Microb Infect 2003; 5:1213-1219; PMID:14623017; http://dx.doi.org/10.1016/j.micinf.2003.08.009.
   PubMed Web of Science ®Google Scholar
• Lipuma J. Update on the Burkholderia cepacia complex. Curr Opin Pulm Med 2005; 11:528-33; PMID:16217180; http://dx.doi.org/10.1097/01.mcp.0000181475.85187.ed.
   PubMed Web of Science ®Google Scholar
• Caraher E, Duff C, Mullen T, Mc Keon S, Murphy P, Callaghan M, McClean S. Invasion and biofilm formation of Burkholderia dolosa is comparable with Burkholderia cenocepacia and Burkholderia multivorans. J Cyst Fibros 2007; 6:49-56; PMID:16781896; http://dx.doi.org/10.1016/j.jcf.2006.05.007.
   PubMed Web of Science ®Google Scholar
• Olivier KN, Weber DJ, Wallace RJ Jr, Faiz AR, Lee JH, Zhang Y, Brown-Elliot BA, Handler A, Wilson RW, Schechter MS, et al. Nontubercu-lous mycobacteria I: multicenter prevalence study in cystic fibrosis. Am J RespirCrit Care Med 2003; 167:828-34; PMID:12433668; http://dx.doi.org/10.1164/rccm.200207-678OC.
   PubMed Web of Science ®Google Scholar
• Leao SC, Tortoli E, Euzeby JP, Garcia MJ. Proposal that Mycobacterium massiliense and Mycobacterium bolletii be united and reclassified as Mycobacterium abscessus subsp. bolletii comb. nov., designation of Mycobacterium abscessus subsp.abscessus subsp. nov. and emended description of Mycobacterium abscessus. IntJ Syst Evol Microbiol 2011; 61:2311-3; PMID:21037035; http://dx.doi.org/10.1099/ijs.0.023770-0.
   PubMed Web of Science ®Google Scholar
• Pierre-Audigier C, Ferroni A, Sermet-Gaudelus I, Le Bourgeois M, Offredo C, Vu-Thien H, Fauroux B, Mariani P, Munck A, Bingen E, et al. Age-related prevalence and distribution of nontuberculousmycobacterial species among patients with cystic fibrosis. J Clin Microbiol 2005; 43:3467-70; PMID:16000480; http://dx.doi.org/10.1128/JCM.43.7.3467-3470.2005.
   PubMed Web of Science ®Google Scholar
• Wallace RJ Jr, Brown BA, Griffith DE. Nosocomial outbreaks/pseudo-outbreaks caused by nontuberculous mycobacteria. Annu Rev Microbiol 1998; 52:453-90; PMID:9891805; http://dx.doi.org/10.1146/annurev.micro.52.1.453.
   PubMed Web of Science ®Google Scholar
• Aitken ML, Limaye A, Pottinger P, Whimbey E, Goss CH, Tonelli MR, Cangelosi GA, Dirac MA, Olivier KN, Brown-Elliott BA, et al. Respiratory outbreak of Mycobacterium abscessus subspecies massiliense in a lung transplant and cystic fibrosis center. Am J Respir Crit Care Med 2012; 185:231-2; PMID:22246710; http://dx.doi.org/10.1164/ajrccm.185.2.231.
   PubMed Web of Science ®Google Scholar
• Bryant JM, Grogono DM, Greaves D, Foweraker J, Roddick I, Inns T, Reacher M, Haworth CS, Curran MD, Harris SR, et al. Whole-genome sequencing to identify transmission of Mycobacterium absces-sus between patients with cystic fibrosis: a retrospective cohort study. Lancet 2013; 381:1551-60; PMID:23541540; http://dx.doi.org/10.1016/S0140-6736(13)60632-7.
   PubMed Web of Science ®Google Scholar
• Ripoll F, Pasek S, Schenowitz C, Dossat C, Barbe V, Rottman M, Macheras E, Heym B, Herrmann JL, Daffé M, et al. Nonmycobacterial virulence genes in the genome of the emerging pathogen Mycobacterium abscessus. PLoS ONE 2009; 4:e5660; PMID:19543527; http://dx.doi.org/10.1371/journal.pone.0005660.
   PubMed Web of Science ®Google Scholar
• Nash KA, Brown-Elliott BA, Wallace RJ Jr. A novel gene, erm(41), confers inducible macrolide resistance to clinical isolates of Mycobacterium abscessus but is absent from Mycobacterium chelonae. Antimicrob Agents Chemother 2009; 53:1367-76; PMID: 19171799; http://dx.doi.org/10.1128/AAC.01275-08.
   PubMed Web of Science ®Google Scholar
• Sanguinetti M, Ardito F, Fiscarelli E, La Sorda M, D'Argenio P, Ricciotti G, Fadda G. Fatal pulmonary infection due to multidrug-resistant Mycobacterium abscessus in a patient with cystic fibrosis. J Clin Microbiol 2001;39:816-9; PMID:11158161; http://dx.doi.org/10.1128/JCM.39.2.816-819.2001.
   PubMed Web of Science ®Google Scholar
• Taylor JL, Palmer SM. Mycobacterium abscessus chest wall and pulmonary infection in a cystic fibrosis lung transplant recipient. J Heart Lung Transplant 2006; 25:985-8; PMID:16890122; http://dx.doi.org/10.1016/j.healun.2006.04.003.
   PubMed Web of Science ®Google Scholar
• Catherinot E, Roux AL, Vibet MA, Bellis G, Ravilly S, Lemonnier L, Le Roux E, Bernède-Bauduin C, Le Bourgeois M, Herrmann JL, et al. Mycobacterium avium and Mycobacterium abscessus complex target distinct cysticfibrosis patient subpopulations. J Cyst Fibros 2013;12:74-80; PMID:22857820; http://dx.doi.org/10.1016/j.jcf.2012.06.009.
   PubMed Web of Science ®Google Scholar
• Lopez AD, Murray CC. The global burden of disease, 1990–2020. Nat Med 1998; 4:1241-3; PMID:9809543; http://dx.doi.org/10.1038/3218.
   PubMed Web of Science ®Google Scholar
• Hoft DF, Brusic V, Sakala IG. Optimizing vaccine development. Cell Microbiol 2011 13:934-942; PMID:21631691; http://dx.doi.org/10.1111/j.1462-5822.2011.01609.x.
   PubMed Web of Science ®Google Scholar
• Le Moigne V, Rottman M, Goulard C, Barteau B, Poncin I, Soismier N, Canaan S, Pitard B, Gaillard JL, Herrmann JL. Bacterial phospholipases C as vaccine candidate antigens against cystic fibrosis respiratory pathogens: the Mycobacterium abscessus model. Vaccine 2015; 33:2118-24; PMID: 25804706; http://dx.doi.org/10.1016/j.vaccine.2015.03.030.
   PubMed Web of Science ®Google Scholar
• Tighe H, Corr M, Roman M, Raz E. Gene vaccination: plasmid DNA is more than just a blueprint. Immunol Today 1998; 19:89-97; PMID:9509764; http://dx.doi.org/10.1016/S0167-5699(97)01201-2.
   PubMedGoogle Scholar
• Klinman DM, Klaschik S, Tross D, Shirota H, Steinhagen F. FDA guidance on prophylactic DNA vaccines: analysis and recommendations. Vaccine 2010; 28:2801-05; PMID:19941989; http://dx.doi.org/10.1016/j.vaccine.2009.11.025.
   PubMed Web of Science ®Google Scholar
• Kutzler MA, Weiner DB. DNA vaccines: ready for prime time? Nat Rev Genet 2008; 9:776-88; PMID:18781156; http://dx.doi.org/10.1038/nrg2432.
   PubMed Web of Science ®Google Scholar
• Tascon RE, Colston MJ, Ragno S, Stavropoulos E, Gregory D, Lowrie DB. Vaccination against tuberculosis by DNA injection. Nat Med 1996; 2:888-92; PMID:8705858; http://dx.doi.org/10.1038/nm0896-888.
   PubMed Web of Science ®Google Scholar
• Huygen K, Content J, Denis O, Montgomery DL, Yawman AM, Deck RR, DeWitt CM, Orme IM, Baldwin S, D'Souza C, et al. Immunogenicity and protective efficacy of a tuberculosis DNA vaccine. Nat Med 1996; 2:893-8; PMID:8705859; http://dx.doi.org/10.1038/nm0896-893.
   PubMed Web of Science ®Google Scholar
• Pillarisetti N, Williamson E, Linnane B, Skoric B, Robertson CF, Robinson P, Massie J, Hall GL, Sly P, Stick S, et al. Infection, inflammation, and lung function decline in infants with cystic fibrosis. Am J Respir Crit Care Med 2011; 184:75-81; PMID:21493738; http://dx.doi.org/10.1164/rccm.201011-1892OC.
   PubMed Web of Science ®Google Scholar
• Sagel SD, Gibson RL, Emerson J, McNamara S, Burns JL, Wagener JS, Ramsey BW; Inhaled Tobramycin in Young Children Study Group; Cystic Fibrosis Foundation Therapeutics Development Network. Impact of pseudomonas and staphylococcal infection on inflammation and clinical status in young children with cystic fibrosis. J Pediatr 2009; 154:183-8; PMID:18822427; http://dx.doi.org/10.1016/j.jpeds.2008.08.001.
   PubMed Web of Science ®Google Scholar
• Grimwood K, Kyd JM, Owen SJ, Massa HM, Cripps AW. Vaccination against respiratory Pseudomonas aeruginosa infection. Hum Vaccin Immunother 2015; 11:14-20; PMID: 25483510; http://dx.doi.org/10.4161/hv.34296.
   PubMed Web of Science ®Google Scholar
• Savoia D. New perspectives in the management of Pseudomonas aeruginosa infections. Future Microbiol 2014; 9:917-28; PMID:25156380; http://dx.doi.org/10.2217/fmb.14.42.
   PubMed Web of Science ®Google Scholar
• Johansen HK, Gøtzsche PC. Vaccines for preventing infection with Pseudomonas aeruginosa in cystic fibrosis. Cochrane Database Syst Rev 2013; 6:CD001399; PMID: 23771707.
   PubMedGoogle Scholar
• Sharma A, Krause A, Worgall S. Recent developments for Pseudomonas vaccines. Hum Vaccin 2011; 7:999-1011; PMID:21941090; http://dx.doi.org/10.4161/hv.7.10.16369.
   PubMed Web of Science ®Google Scholar
• Pier G. Application of vaccine technology to prevention of Pseudomonas aeruginosa infections. Expert Rev Vaccines 2005; 4:645-56; PMID:16221066; http://dx.doi.org/10.1586/14760584.4.5.645.
   PubMed Web of Science ®Google Scholar
• Döring G, Pfeiffer C, Weber U, Mohr-Pennert A, Dorner F. Parenteral application of a Pseudomonas aeruginosa flagella vaccine elicits specific anti-flagella antibodies in the airways of healthy individuals. Am J Respir Crit Care Med 1995; 151, 983-985; PMID:7697276.
   PubMed Web of Science ®Google Scholar
• Döring G, Meisner C, Stern M; Flagella Vaccine Trial Study Group. Flagella vaccine trial study, a double-blind randomized placebo-controlled phase III study of a Pseudomonas aeruginosa flagella vaccine in cystic fibrosis patients. Proc Natl Acad Sci USA 2007; 104:11020-5; PMID:17585011; http://dx.doi.org/10.1073/pnas.0702403104.
   PubMed Web of Science ®Google Scholar
• Bumann D, Behre C, Behre K, Herz S, Gewecke B, Gessner JE, von Specht BU, Baumann U. Systemic, nasal and oral live vaccines against Pseudomonas aeruginosa: a clinical trial of immunogenicity in lower airways of human volunteers. Vaccine 2010; 28:707-13; PMID:19887136; http://dx.doi.org/10.1016/j.vaccine.2009.10.080.
   PubMed Web of Science ®Google Scholar
• Weimer ET, Lu H, Kock ND, Wozniak DJ, Mizel SB. A fusion protein vaccine containing OprF epitope 8, OprI, and type A and B flagellins promotes enhanced clearance of nonmucoid Pseudomonas aeruginosa. Infect Immun 2009; 77:2356-66; PMID:19349426; http://dx.doi.org/10.1128/IAI.00054-09.
   PubMed Web of Science ®Google Scholar
• Sorichter S, Baumann U, Baumgart A, Walterspacher S, von Specht BU. Immune responses in the airways by nasal vaccination with systemic boosting against Pseudomonas aeruginosa in chronic lung disease. Vaccine 2009; 27:2755-9; PMID:19366571; http://dx.doi.org/10.1016/j.vaccine.2009.03.010.
   PubMed Web of Science ®Google Scholar
• Farjah A, Owlia P, Siadat SD, Mousavi SF, Ardestani MS, Mohammadpour HK. Immunological evaluation of an alginate-based conjugate as a vaccine candidate against Pseudomonas aeruginosa. APMIS 2015; 123:175-83; PMID:25470757; http://dx.doi.org/10.1111/apm.12337.
   PubMed Web of Science ®Google Scholar
• Zuercher AW, Horn MP, Que JU, Ruedeberg A, Schoeni MH, Schaad UB, Marcus P, Lang AB. Antibody responses induced by long-term vaccination with an octovalent conjugate Pseudomonas aeruginosa vaccine in children with cystic fibrosis. FEMS Immunol Med Microbiol 2006; 47:302-8; PMID:16831219; http://dx.doi.org/10.1111/j.1574-695X.2006.00103.x.
   PubMed Web of Science ®Google Scholar
• Zuercher AW, Imboden MA, Jampen S, Bosse D, Ulrich M, Chtioui H, Lauterburg BH, Lang AB. Cellular immunity in healthy volunteers treated with an octavalent conjugate Pseudomonas aeruginosa vaccine. Clin Exp Immunol 2006; 143:132-8; PMID:16367944; http://dx.doi.org/10.1111/j.1365-2249.2005.02964.x.
   PubMed Web of Science ®Google Scholar
• Campodónico VL, Llosa NJ, Bentancor LV, Maira-Litran T, Pier GB. Efficacy of a conjugate vaccine containing polymannuronic acid and flagellin against experimental Pseudomonas aeruginosa lung infection in mice. Infect Immun 2011; 79:3455-64; PMID: 21628521; http://dx.doi.org/10.1128/IAI.00157-11.
   PubMed Web of Science ®Google Scholar
• Rodrigues NF, van Tilburg Bernardes E, Rocha RP, da Costa LC, Coutinho AC, dos Santos Muniz M, Pereira AA, da Silva PH, Malaquias LC, Coelho LF. Bovine serum albumin nanoparticle vaccine reduces lung pathology induced by live Pseudomonas aeruginosa infection in mice. Vaccine 2013; 31:5062-6; PMID: 24021308; http://dx.doi.org/10.1016/j.vaccine.2013.08.078.
   PubMed Web of Science ®Google Scholar
• Casey WT, McClean S. Exploiting molecular virulence determinants in Burkholderia to develop vaccine antigens. Curr Med Chem 2015; 22:1719-33; PMID:25850766; http://dx.doi.org/10.2174/0929867322666150408111304.
   PubMed Web of Science ®Google Scholar
• Shinoy M, Dennehy R, Coleman L, Carberry S, Schaffer K, Callaghan M, Doyle S, McClean S. Immunoproteomic analysis of proteins expressed by two related pathogens, Burkholderia multivorans and Burkholderia cenocepacia, during human infection. PLoS One 2013; 8:e80796; PMID: 24260482; http://dx.doi.org/10.1371/journal.pone.0080796.
   PubMed Web of Science ®Google Scholar
• Choh LC, Ong GH, Vellasamy KM, Kalaiselvam K, Kang WT, Al-Maleki AR, Mariappan V, Vadivelu J. Burkholderia vaccines: are we moving forward? Front Cell Infect Microbiol 2013; 5;3:5; PMID:23386999.
   PubMed Web of Science ®Google Scholar
• Musson JA, Reynolds CJ, Rinchai D, Nithichanon A, Khaenam P, Favry E, Spink N, Chu KK, De Soyza A, Bancroft GJ, et al. CD4 + T cell epitopes of FliC conserved between strains of Burkholderia: implications for vaccines against melioidosis and cepacia complex in cystic fibrosis. J Immunol 2014; 193:6041-9; PMID:25392525; http://dx.doi.org/10.4049/jimmunol.1402273.
   PubMed Web of Science ®Google Scholar
• Makidon PE, Knowlton J, Groom JV 2nd, Blanco LP, LiPuma JJ, Bielinska AU, Baker JR Jr. Induction of immune response to the 17 kDa OMPA Burkholderia cenocepacia polypeptide and protection against pulmonary infection in mice after nasal vaccination with an OMP nanoemulsion-based vaccine. Med Microbiol Immunol 2010; 199:81-92; PMID: 19967396; http://dx.doi.org/10.1007/s00430-009-0137-2.
   PubMed Web of Science ®Google Scholar
• Bertot GM, Restelli MA, Galanternik L, Aranibar Urey RC, Valvano MA, Grinstein S. Nasal immunization with Burkholderia multivorans outer membrane proteins and the mucosal adjuvant adamantylamide dipeptide confers efficient protection against experimental lung infections with B. multivorans and B. cenocepacia. Infect Immun 2007; 75:2740-52; PMID: 17296759; http://dx.doi.org/10.1128/IAI.01668-06.
   PubMed Web of Science ®Google Scholar
• World Health Organization. Global tuberculosis report 2013. Available at www.who.int/iris/bitstream/10665/91355/1/9789241564656_eng.pdf
   Google Scholar
• Jenner E. The Three Original Publications on Vaccination Against Smallpox. 1798, 1799, 1800. New York: P.F. Collier & Son Company, 1909–14. Harvard Classics, Vol. 38, Part 4.
   Google Scholar
• Montgomery DL, Huygen K, Yawman AM, Deck RR, Dewitt CM, Content J, Liu MA, Ulmer JB. Induction of humoral and cellular immune responses by vaccination with M. tuberculosis antigen 85 DNA. Cell Mol Biol (Noisy-le-grand) 1997; 43:285-92; PMID:9193782.
   PubMed Web of Science ®Google Scholar
• Chambers MA, Vordermeier H, Whelan A, Commander N, Tascon R, Lowrie D, Hewinson RG. Vaccination of mice and cattle with plasmid DNA encoding the Mycobacterium bovis antigen MPB83. Clin Infect Dis 2000; Suppl 3:S283-7. PMID:10875801; http://dx.doi.org/10.1086/313875.
   PubMedGoogle Scholar
• Vordermeier HM, Whelan A, Cockle PJ, Farrant L, Palmer N, Hewinson RG. Use of synthetic peptides derived from the antigens ESAT-6 and CFP-10 for differential diagnosis of bovine tuberculosis in cattle. Clin Diagn Lab Immunol 2001; 8:571-8; PMID:11329460.
   PubMedGoogle Scholar
• Huygen K. On the use of DNA vaccines for the prophylaxis of mycobacterial diseases. Infect Immun 2003; 71:1613-21; PMID:12654772; http://dx.doi.org/10.1128/IAI.71.4.1613-1621.2003.
   PubMed Web of Science ®Google Scholar
• Romano M, Huygen K. DNA vaccines against mycobacterial diseases. Expert Rev Vaccines 2009; 8:1237-50; PMID:19722896; http://dx.doi.org/10.1586/erv.09.87.
   PubMed Web of Science ®Google Scholar
• Oksanen KE, Halfpenny NJ, Sherwood E, Harjula SK, Hammarén MM, Ahava MJ, Pajula ET, Lahtinen MJ, Parikka M, Rämet M. An adult zebrafish model for preclinical tuberculosis vaccine development. Vaccine 2013; 31:5202-9; PMID:24055305; http://dx.doi.org/10.1016/j.vaccine.2013.08.093.
   PubMed Web of Science ®Google Scholar
• Feng G, Jiang Q, Xia M, Lu Y, Qiu W, Zhao D, Lu L, Peng G, Wang Y. Enhanced immune response and protective effects of nano-chitosan-based DNA vaccine encoding T cell epitopes of Esat-6 and FL against Mycobacterium tuberculosis infection. PLoS One 2013; 8:e61135; PMID:23637790; http://dx.doi.org/10.1371/journal.pone.0061135.
   PubMed Web of Science ®Google Scholar
• Martin E, Roche PW, Triccas JA, Britton WJ. DNA encoding a single mycobacterial antigen protects against leprosy infection. Vaccine 2001; 19:1391-6. PMID:11163661; http://dx.doi.org/10.1016/S0264-410X(00)00374-1.
   PubMed Web of Science ®Google Scholar
• Martin E, Kamath AT, Triccas JA, Britton WJ. Protection against virulent Mycobacterium avium infection following DNA vaccination with the 35-kgdalton antigen is accompanied by induction of gamma interferon-secreting CD4(+) T cells. Infect Immun 2000; 68:3090-6; PMID:10816448; http://dx.doi.org/10.1128/IAI.68.6.3090-3096.2000.
   PubMed Web of Science ®Google Scholar
• Velaz-Faircloth M, Cobb AJ, Horstman AL, Henry SC, Frothingham R. Protection against Mycobacterium avium by DNA vaccines expressing mycobacterial antigens as fusion proteins with green fluorescent protein. Infect Immun 1999; 67:4243-50; PMID:10417198.
   PubMed Web of Science ®Google Scholar
• Tanghe A, Content J, Van Vooren JP, Portaels F, Huygen K. Protective efficacy of a DNA vaccine encoding antigen 85A from Mycobacterium bovis BCG against Buruli ulcer. Infect Immun 2001; 69:5403-11; PMID:11500410; http://dx.doi.org/10.1128/IAI.69.9.5403-5411.2001.
   PubMed Web of Science ®Google Scholar
• Morand PC, Burgel PR, Carlotti A, Desmazes-Dufeu N, Farhi D, Martin C, Kanaan R, Mangialavori L, Palangié E, Dusser D, et al. Mediastinal tuberculosis in an adult patient with cystic fibrosis. J Clin Microbiol 2011; 49:750-1; PMID:21106788; http://dx.doi.org/10.1128/JCM.01313-10.
   PubMed Web of Science ®Google Scholar
• Asherova IK, Feigelson J, Vasilyeva LA, Gabitov VJ. Cystic fibrosis complicated by multiresistant tuberculosis. Acta Paediatr 2006; 95:1513-4; PMID:17062491; http://dx.doi.org/10.1080/08035250600724515.
   PubMed Web of Science ®Google Scholar
• Bakala N'Goma JC, Le Moigne V, Soismier N, Laencina L, Le Chevalier F, Roux AL, Poncin I, Serveau-Avesque C, Rottman M, Gaillard JL, et al. Mycobacterium abscessus Phospholipase C expression is induced during coculture within amoebae and enhances M. abscessus virulence in mice. Infect Immun 2015; 83:780-91; PMID:25486995; http://dx.doi.org/10.1128/IAI.02032-14.
   PubMed Web of Science ®Google Scholar
• van Doorninck JH, French PJ, Verbeek E, Peters RH, Morreau H, Bijman J, Scholte BJ. A mouse model for the cystic fibrosis delta F508 mutation. EMBO J 1995; 14:4403-11; PMID:7556083.
   PubMed Web of Science ®Google Scholar
• Roux AL, Ray A, Pawlik A, Medjahed H, Etienne G, Rottman M, Catherinot E, Coppée JY, Chaoui K, Monsarrat B, et al. Overexpression of proinflammatory TLR-2-signalling lipoproteins in hypervirulent mycobacterial variants. Cell Microbiol 2011; 13:692-704; PMID:21143571; http://dx.doi.org/10.1111/j.1462-5822.2010.01565.x.
   PubMed Web of Science ®Google Scholar
• Malfroot A, Adam G, Ciofu O, Döring G, Knoop C, Lang AB, Van Damme P, Dab I, Bush A; European Cystic Fibrosis Society (ECFS) Vaccination Group. Immunisation in the current management of cystic fibrosis patients. J Cyst Fibros 2005; 4:77-87; PMID:15978534; http://dx.doi.org/10.1016/j.jcf.2004.10.003.
   PubMedGoogle Scholar